Medtronic has obtained the European CE-Mark for its insulin delivery device called MiniMed 670G hybrid closed loop system which has been designed to treat type 1 diabetes patients aged seven years and above.

The system can automate and personalise basal insulin delivery. It features Medtronic’s SmartGuard technology and Guardian Sensor 3, a continuous glucose monitor (CGM).

Companies Intelligence

View all

Together, the technology and CGM enable self-adjustment of basal insulin delivery in order to provide protection from both high and low levels.

“The system can automate and personalise basal insulin delivery. It features Medtronic’s SmartGuard technology and Guardian Sensor 3, a continuous glucose monitor.”

Medtronic Advanced Insulin Management division president Alejandro Galindo said: “The MiniMed 670G system advances our ability to automatically suspend and resume insulin delivery to the next level by automating self-adjusting basal insulin delivery every five minutes based on sensor glucose values – providing the most advanced algorithm available to deliver leading clinical outcomes.”

Medtronic, in collaboration with strategic technology partner IBM Watson Health, has also launched the Sugar.IQ smart diabetes management app.

Intended to simplify and improve daily management of the condition, the app is powered by IBM Watson’s artificial intelligence (AI) and analytic technologies.

Sugar.IQ continuously tracks the response of glucose level to food intake, insulin dosages and daily routines, among other factors, in turn aiding patients to make daily management decisions.

Medtronic is providing the app to users of its Guardian Connect system, a smart CGM device for diabetes patients using multiple daily injections (MDI). The system offers actionable tools to manage high and low glucose levels.

The Sugar.IQ assistant app is available for iOS-based mobile devices in the US.